Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer
This study aimed to analyze the clinical effects of dendritic cell (DC) and cytokine-induced killer (CIK) immunotherapy combined with chemotherapy on patients with metastatic breast cancer. Twenty patients were included into this study who were diagnosed as metastatic breast cancer (MBC). DC and CIK...
Gespeichert in:
| Veröffentlicht in: | Pakistan journal of pharmaceutical sciences 2015-05, Vol.28 (3 Suppl), p.1055-1058 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1058 |
|---|---|
| container_issue | 3 Suppl |
| container_start_page | 1055 |
| container_title | Pakistan journal of pharmaceutical sciences |
| container_volume | 28 |
| creator | Mao, Qixin Li, Lianfang Zhang, Chongjian Sun, Yadong Liu, Shanqing Cui, Shude |
| description | This study aimed to analyze the clinical effects of dendritic cell (DC) and cytokine-induced killer (CIK) immunotherapy combined with chemotherapy on patients with metastatic breast cancer. Twenty patients were included into this study who were diagnosed as metastatic breast cancer (MBC). DC and CIK were augmented by in vitro culture and then rein fused into body through vein.The pain relief rate (RR), toxic and side effects of chemotherapy, immunity functions and living quality of patients were observed. DC and CIK cells were induced by the autologous peripheral blood mononuclear cells (PBMC). Meanwhile, flow cytometry was used to measure T cell subsets and natural killer T (NKT) cells in patients in the two groups before and after the biological treatment. After DC and CIK were rein fused into the patients body, no severe side-effect was found. It was also found that cellular immunotherapy combined with chemotherapy the immunotherapy of cells improved the immunity, the living quality of patients and the disease control rate (DCR). In conclusion, cellular immunotherapy produces small side effects; it combined with chemotherapyis able to improve the DCR and living quality of patients and prolong their lives. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1686996310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1686996310</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-4bbbc1a369a97dbddc4978d23a9fe1a475821204b266c678c0838e547724fead3</originalsourceid><addsrcrecordid>eNo90LtOwzAYBeAMIFoKr4A8skSyHdeXEYVbRSUWkNgiX_5Qo9gJsSPUtyeUwnSko09nOCfFkmBCSo7J26I4T-kDY86UUmfFgnK8JoLIZbGvOx-91R2CtgWbE-pb5EOYYp93MOph_1Pc1mW9eUK2D8ZHcOjL5x2yOwj_yEeUR9DZx3c0zAFxnjqwAFmnPFcWmVmkjKyOFsaL4rTVXYLLY66K1_u7l_qx3D4_bOqbbTlQQnLJjDGW6IorrYQzzlmmhHS00qoFoplYS0ooZoZybrmQFstKwpoJQVkL2lWr4vp3dxj7zwlSboJPFrpOR-in1BAuuVK8InimV0c6mQCuGUYf9Lhv_u6qvgGPl2dn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1686996310</pqid></control><display><type>article</type><title>Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Mao, Qixin ; Li, Lianfang ; Zhang, Chongjian ; Sun, Yadong ; Liu, Shanqing ; Cui, Shude</creator><creatorcontrib>Mao, Qixin ; Li, Lianfang ; Zhang, Chongjian ; Sun, Yadong ; Liu, Shanqing ; Cui, Shude</creatorcontrib><description>This study aimed to analyze the clinical effects of dendritic cell (DC) and cytokine-induced killer (CIK) immunotherapy combined with chemotherapy on patients with metastatic breast cancer. Twenty patients were included into this study who were diagnosed as metastatic breast cancer (MBC). DC and CIK were augmented by in vitro culture and then rein fused into body through vein.The pain relief rate (RR), toxic and side effects of chemotherapy, immunity functions and living quality of patients were observed. DC and CIK cells were induced by the autologous peripheral blood mononuclear cells (PBMC). Meanwhile, flow cytometry was used to measure T cell subsets and natural killer T (NKT) cells in patients in the two groups before and after the biological treatment. After DC and CIK were rein fused into the patients body, no severe side-effect was found. It was also found that cellular immunotherapy combined with chemotherapy the immunotherapy of cells improved the immunity, the living quality of patients and the disease control rate (DCR). In conclusion, cellular immunotherapy produces small side effects; it combined with chemotherapyis able to improve the DCR and living quality of patients and prolong their lives.</description><identifier>ISSN: 1011-601X</identifier><identifier>PMID: 26051718</identifier><language>eng</language><publisher>Pakistan</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - immunology ; Breast Neoplasms - pathology ; Breast Neoplasms - psychology ; Breast Neoplasms - therapy ; Cells, Cultured ; Chemotherapy, Adjuvant ; Cytokine-Induced Killer Cells - immunology ; Cytokine-Induced Killer Cells - transplantation ; Dendritic Cells - immunology ; Dendritic Cells - transplantation ; Female ; Humans ; Immunity, Cellular ; Immunotherapy, Adoptive - adverse effects ; Immunotherapy, Adoptive - methods ; Middle Aged ; Neoplasm Metastasis ; Quality of Life ; Time Factors ; Treatment Outcome</subject><ispartof>Pakistan journal of pharmaceutical sciences, 2015-05, Vol.28 (3 Suppl), p.1055-1058</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26051718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mao, Qixin</creatorcontrib><creatorcontrib>Li, Lianfang</creatorcontrib><creatorcontrib>Zhang, Chongjian</creatorcontrib><creatorcontrib>Sun, Yadong</creatorcontrib><creatorcontrib>Liu, Shanqing</creatorcontrib><creatorcontrib>Cui, Shude</creatorcontrib><title>Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer</title><title>Pakistan journal of pharmaceutical sciences</title><addtitle>Pak J Pharm Sci</addtitle><description>This study aimed to analyze the clinical effects of dendritic cell (DC) and cytokine-induced killer (CIK) immunotherapy combined with chemotherapy on patients with metastatic breast cancer. Twenty patients were included into this study who were diagnosed as metastatic breast cancer (MBC). DC and CIK were augmented by in vitro culture and then rein fused into body through vein.The pain relief rate (RR), toxic and side effects of chemotherapy, immunity functions and living quality of patients were observed. DC and CIK cells were induced by the autologous peripheral blood mononuclear cells (PBMC). Meanwhile, flow cytometry was used to measure T cell subsets and natural killer T (NKT) cells in patients in the two groups before and after the biological treatment. After DC and CIK were rein fused into the patients body, no severe side-effect was found. It was also found that cellular immunotherapy combined with chemotherapy the immunotherapy of cells improved the immunity, the living quality of patients and the disease control rate (DCR). In conclusion, cellular immunotherapy produces small side effects; it combined with chemotherapyis able to improve the DCR and living quality of patients and prolong their lives.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - psychology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cells, Cultured</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cytokine-Induced Killer Cells - immunology</subject><subject>Cytokine-Induced Killer Cells - transplantation</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - transplantation</subject><subject>Female</subject><subject>Humans</subject><subject>Immunity, Cellular</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Quality of Life</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1011-601X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90LtOwzAYBeAMIFoKr4A8skSyHdeXEYVbRSUWkNgiX_5Qo9gJsSPUtyeUwnSko09nOCfFkmBCSo7J26I4T-kDY86UUmfFgnK8JoLIZbGvOx-91R2CtgWbE-pb5EOYYp93MOph_1Pc1mW9eUK2D8ZHcOjL5x2yOwj_yEeUR9DZx3c0zAFxnjqwAFmnPFcWmVmkjKyOFsaL4rTVXYLLY66K1_u7l_qx3D4_bOqbbTlQQnLJjDGW6IorrYQzzlmmhHS00qoFoplYS0ooZoZybrmQFstKwpoJQVkL2lWr4vp3dxj7zwlSboJPFrpOR-in1BAuuVK8InimV0c6mQCuGUYf9Lhv_u6qvgGPl2dn</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Mao, Qixin</creator><creator>Li, Lianfang</creator><creator>Zhang, Chongjian</creator><creator>Sun, Yadong</creator><creator>Liu, Shanqing</creator><creator>Cui, Shude</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201505</creationdate><title>Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer</title><author>Mao, Qixin ; Li, Lianfang ; Zhang, Chongjian ; Sun, Yadong ; Liu, Shanqing ; Cui, Shude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-4bbbc1a369a97dbddc4978d23a9fe1a475821204b266c678c0838e547724fead3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - psychology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cells, Cultured</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cytokine-Induced Killer Cells - immunology</topic><topic>Cytokine-Induced Killer Cells - transplantation</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - transplantation</topic><topic>Female</topic><topic>Humans</topic><topic>Immunity, Cellular</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Quality of Life</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mao, Qixin</creatorcontrib><creatorcontrib>Li, Lianfang</creatorcontrib><creatorcontrib>Zhang, Chongjian</creatorcontrib><creatorcontrib>Sun, Yadong</creatorcontrib><creatorcontrib>Liu, Shanqing</creatorcontrib><creatorcontrib>Cui, Shude</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pakistan journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mao, Qixin</au><au>Li, Lianfang</au><au>Zhang, Chongjian</au><au>Sun, Yadong</au><au>Liu, Shanqing</au><au>Cui, Shude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer</atitle><jtitle>Pakistan journal of pharmaceutical sciences</jtitle><addtitle>Pak J Pharm Sci</addtitle><date>2015-05</date><risdate>2015</risdate><volume>28</volume><issue>3 Suppl</issue><spage>1055</spage><epage>1058</epage><pages>1055-1058</pages><issn>1011-601X</issn><abstract>This study aimed to analyze the clinical effects of dendritic cell (DC) and cytokine-induced killer (CIK) immunotherapy combined with chemotherapy on patients with metastatic breast cancer. Twenty patients were included into this study who were diagnosed as metastatic breast cancer (MBC). DC and CIK were augmented by in vitro culture and then rein fused into body through vein.The pain relief rate (RR), toxic and side effects of chemotherapy, immunity functions and living quality of patients were observed. DC and CIK cells were induced by the autologous peripheral blood mononuclear cells (PBMC). Meanwhile, flow cytometry was used to measure T cell subsets and natural killer T (NKT) cells in patients in the two groups before and after the biological treatment. After DC and CIK were rein fused into the patients body, no severe side-effect was found. It was also found that cellular immunotherapy combined with chemotherapy the immunotherapy of cells improved the immunity, the living quality of patients and the disease control rate (DCR). In conclusion, cellular immunotherapy produces small side effects; it combined with chemotherapyis able to improve the DCR and living quality of patients and prolong their lives.</abstract><cop>Pakistan</cop><pmid>26051718</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1011-601X |
| ispartof | Pakistan journal of pharmaceutical sciences, 2015-05, Vol.28 (3 Suppl), p.1055-1058 |
| issn | 1011-601X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1686996310 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - immunology Breast Neoplasms - pathology Breast Neoplasms - psychology Breast Neoplasms - therapy Cells, Cultured Chemotherapy, Adjuvant Cytokine-Induced Killer Cells - immunology Cytokine-Induced Killer Cells - transplantation Dendritic Cells - immunology Dendritic Cells - transplantation Female Humans Immunity, Cellular Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Middle Aged Neoplasm Metastasis Quality of Life Time Factors Treatment Outcome |
| title | Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T17%3A44%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20effects%20of%20immunotherapy%20of%20DC-CIK%20combined%20with%20chemotherapy%20in%20treating%20patients%20with%20metastatic%20breast%20cancer&rft.jtitle=Pakistan%20journal%20of%20pharmaceutical%20sciences&rft.au=Mao,%20Qixin&rft.date=2015-05&rft.volume=28&rft.issue=3%20Suppl&rft.spage=1055&rft.epage=1058&rft.pages=1055-1058&rft.issn=1011-601X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1686996310%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1686996310&rft_id=info:pmid/26051718&rfr_iscdi=true |